Bombardieri G, Gigli G L, Bernardi L, Ferri R, Grassi C, Milani A
Hepatogastroenterology. 1985 Feb;32(1):3-7.
In fourteen subjects with various stages of hepatic encephalopathy (HE), Visual Evoked Potential (VEP) recording and blood ammonia (NH3), octopamine (OCT) and phenylethanolamine (PEA) determinations were performed before and during a four-day treatment with branched chain amino acid (BCAA) i.v. infusion. All the subjects with HE showed significant basal VEP alterations, namely an increased latency and a lowered amplitude of the P100 wave, in comparison with a control group of 26 normal subjects. A significant improvement in P100 wave amplitude occurred just about 60' after the beginning of BCAA infusion, while P100 latency was still unaffected, as were OCT, PEA and NH3 levels. After the fourth day of BCAA treatment, both P100 wave amplitudes and latencies were strongly improved, together with OCT, PEA and NH3 levels. VEP improvements seemed to be well correlated with HE clinical evolution, and were able to detect modifications of central nervous system reactivity earlier than serum parameters.
对14例处于不同阶段肝性脑病(HE)的患者,在静脉输注支链氨基酸(BCAA)进行为期四天的治疗之前和治疗期间,进行了视觉诱发电位(VEP)记录以及血氨(NH3)、章鱼胺(OCT)和苯乙醇胺(PEA)测定。与26名正常受试者组成的对照组相比,所有HE患者均表现出明显的基础VEP改变,即P100波潜伏期延长和波幅降低。BCAA输注开始约60分钟后,P100波幅有显著改善,而P100潜伏期仍未受影响,OCT、PEA和NH3水平也是如此。BCAA治疗第四天之后,P100波幅和潜伏期以及OCT、PEA和NH3水平均有显著改善。VEP的改善似乎与HE的临床进展密切相关,并且比血清参数更早地检测到中枢神经系统反应性的改变。